Navigation Links
Insulin Administration and Nutritional Therapy Requires Standardized Coordination, Says ECRI Institute PSO

PLYMOUTH MEETING, Pa., Nov. 15, 2012 /PRNewswire-USNewswire/ -- Insulin has consistently been declared a high-alert medication due to the risks associated with its prescribing and dosing. When a nutrition order for a patient is modified, the patient's insulin regimen may inadvertently remain unreviewed or unchanged. ECRI Institute Patient Safety Organization (PSO) has seen both events and research requests pertaining to this issue.


"Because diabetic and non-diabetic patients receiving nutritional therapy and insulin are often managed by more than one practitioner, facilities need to implement a standardized process to ensure coordinated care," states Karen P. Zimmer, MD, MPH, FAAP, medical director, ECRI Institute PSO. "Yet when we further explored this topic, there was minimal literature that discussed best practices and among the hospitals we approached, there was no consensus on how to best go about this. The analysis of aggregated reports continues to reveal gaps that we need to address."

ECRI Institute PSO's recently released Patient Safety E-lert, "It's More Than Counting Carbs, It's Communication and Coordination: Insulin Administration and Nutritional Therapy," highlights this patient safety issue involving patients who are receiving enteral or total parenteral nutrition and insulin. The issue came to light when ECRI Institute PSO analyzed reports submitted by participating healthcare providers. As part of its mission to research the best approaches to improving patient care, ECRI Institute is sharing this special E-lert with the healthcare community.

"Reports submitted to Patient Safety Organizations can surface less-known or undetected risks, like those highlighted in this report," states Barbara Rebold, RN, MS, CPHQ, director of operations, ECRI Institute PSO. "We want to share the potential risk we are seeing in our PSO reports and recommend ways to prevent or mitigate that risk."

For questions about this topic, or for information about ECRI Institute PSO, contact ECRI Institute by telephone at (610) 825-6000, ext. 5558; by e-mail at; by fax at (610) 834-1275, or by mail at 5200 Butler Pike, Plymouth Meeting, PA 19462-1298, USA. To sign up for the PSO Monthly Brief, a free eNewsletter comprised of a brief article each month to help keep readers informed about Patient Safety Organizations, go to

About ECRI Institute
For nearly 45 years, ECRI Institute's work in patient safety, adverse event reporting and analysis, and development of recommendations has improved patient care at hospitals and other providers around the world. The ECRI Institute Patient Safety Organization is a component of ECRI Institute, a nonprofit 501(c)(3) organization dedicated to improving the safety, quality, and cost-effectiveness of patient care. ECRI Institute has a long history of investigating adverse events and publishing authoritative risk reduction strategies. ECRI Institute is designated as an Evidence-based Practice Center by the U.S. Agency for Healthcare Research and Quality. ECRI Institute developed and implements the Pennsylvania Patient Safety Reporting System, a mandatory error and near-miss reporting program for Pennsylvania hospitals and other healthcare facilities, under contract to the Pennsylvania Patient Safety Authority, winner of the 2006 John M. Eisenberg Award. For more information, visit Find ECRI Institute on Facebook ( and Twitter (

Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Diabetes Care Devices Market to 2018 - Integrated Insulin Pumps with Continuous Glucose Monitoring Technology to Add a New Dimension to Diabetes Management
2. Insulin degludec and insulin degludec/insulin aspart receive positive vote for approval from FDA Advisory Committee
3. Lilly to Expand Indianapolis Insulin Manufacturing Operations
4. Global Insulin Market Expected to Reach USD 32,346.7 Million in 2018, with China Alone Accounting for 10.2%: Transparency Market Research
5. Biodel Announces Phase 2 Clinical Trial Initiation Of Ultra-Rapid-Acting Insulin Candidate BIOD-123
6. montméd, Inc. to Market FRiO Insulin Wallets in 20 countries of Middle East and North Africa
7. In Pilot Study, a Peptide Controls Blood Sugar in People with Congenital Hyperinsulinism
8. Biodel Awarded NIH Grant to Develop Concentrated Ultra-Rapid-Acting Insulin Formulations for Use in Artificial Pancreas
9. FDA clears Accu-Chek Combo system - Roches new interactive insulin pump system for people with diabetes
10. Lilly and Boehringer Ingelheim Present Data at the 72nd American Diabetes Association Scientific Sessions® from Phase II Studies Comparing Investigational Novel Basal Insulin to Insulin Glargine
11. Halozymes Ultrafast Insulin Formulations Improved Postprandial Glycemic Control in Patients Living with Type 1 Diabetes: Phase 2 Study Results Presented at ADA 2012
Post Your Comments:
(Date:12/1/2015)... , Dec. 1, 2015 Building on ... Johnson & Johnson (NYSE: JNJ ) today ... Pharmaceutical Companies to significantly reduce the burden of ... up 74 percent of new HIV infections among ... World AIDS Day, these new initiatives include collaborations ...
(Date:12/1/2015)... 01, 2015 ... addition of the "2016 Europe ... E. Coli, Enterovirus, Rhinovirus, Rotavirus, Salmonella, ... their offering. --> ... the "2016 Europe Enteric Disease ...
(Date:12/1/2015)... Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company ... today that the company will present at the LD Micro ... the Luxe Sunset Boulevard Hotel in Los Angeles, ... Therapeutics, will present on Thursday, December 3, at 9:00 am ... Please register at least 10 minutes prior to the start ...
Breaking Medicine Technology:
(Date:12/1/2015)... (PRWEB) , ... December 01, 2015 , ... ... at the 7th Annual 2015 Golden Bridge Business Awards under the New Products ... a zero capex web based sample management software that helps labs ...
(Date:12/1/2015)... , ... December 01, 2015 , ... ... medical images have been lifted as IMAGE Information Systems launches MED-TAB™ -- the ... North America Annual Meeting from November 29 to December 4, 2015. , ...
(Date:12/1/2015)... ... December 01, 2015 , ... The importance of ... is the focus of numerous abstracts accepted for presentation here, at the 101st ... Nine abstracts highlight the use of Volpara Solutions’ quantitative breast imaging software tools ...
(Date:12/1/2015)... (PRWEB) , ... December 01, 2015 , ... ... their independence is everything. That is why Hollister Incorporated has launched the VaPro ... offer this next product in the VaPro touch free catheter portfolio,” said Michael ...
(Date:12/1/2015)... Francisco, CA (PRWEB) , ... December 01, 2015 ... ... Behavioral Health Center of Excellence (BHCOE) today announced that the organization has awarded ... in San Francisco, with a Distinguished Award. The award celebrates exceptional special needs ...
Breaking Medicine News(10 mins):